Rajkumar Ganesan

Company: Amgen Inc.

Job title: Executive Director, Oncology

Seminars:

Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers 9:30 am

Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment? Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?Read more

day: Conference Day 2

Roundtable Discussion: Resistance Risks? Comparing Cell Engagers to Alternate Cancer Treatments Such as ADCs & Cell Therapies to Evaluate Potential Risks 12:00 pm

Question the learnings from alternate therapeutic strategies such as how CAR T developers manage CRS Balance how cell engagers can fit into the standard of care or following patient treatment with these therapies Discuss future directions and the looming risk of resistance. Can we prevent it ever developing?Read more

day: Conference Day 1